EFFECT OF ROSUVASTATIN AND ITS COMBINATION WITH FENOFIBRIC ACID ON PRO-INFLAMMATORY CYTOKINES IN ELDERLY PATIENTS AFTER ENDOVASCULAR INTERVENTION
Keywords:
IHD, percutaneous coronary intervention, pro-inflammatory cytokines, rosuvastatin, fenofibric acid, IL-6, TNF-α, CRPAbstract
Ischemic heart disease (IHD) remains the leading cause of death in elderly patients. However, effective work on the management of patients with coronary artery disease to improve the quality of life is performed by percutaneous coronary interventions (PCI). The aim of our study was to investigate the pro-inflammatory efficacy of rosuvastatin and its combination with fenofibric acid in elderly patients with coronary artery disease undergoing percutaneous coronary intervention. In this article, it was analyzed that the majority of patients were elderly and diagnosed with coronary artery disease, stable angina III-IV FC. 109 patients were examined, the average age was 65.3±0.4 years. Analyzing the level of the lipid profile after 6 and 12 months while taking double lipid-lowering therapy with rosuvastatin at a dose of 20 mg and fenofibric acid at a dose of 145 mg, they approached the normative values. The level of all pro-inflammatory cytokines - IL-6, CRP and TNF-α tended to decrease, which proves the pleiotropic effects of statins. As well as indicators of quality of life and end points in the long-term follow-up period were studied.
References
Ambrosova T.N. Therapeutic correction of atherogenic dyslipidemia in metabolic syndrome. International medical journal. 2013.
Barsukov A.V., Talantseva M.S., Sveklina T.S. and others. Lipid-lowering therapy in elderly patients. The focus is on statins and prognosis. Arterial hypertension. 2011.17(5). pp. 415-424.
Bugaenko V.V. Gender features of diagnosis, course and treatment of coronary heart disease. Ukrainian cardiology journal. 2015. №6. pp.100-112.
Ivanov D. O., Aleksandrovich Yu. S., Pshenisnov K. V. et al. Diseases of the cardiovascular system as a cause of death in the Russian Federation: ways to solve the problem. Medicine and healthcare organization, 2019. 4(2), pp.4-12.
Kutishenko N.P., Tolpygina S.N., Lukina Yu.V. Efficiency and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. Rational pharmacotherapy in cardiology 2011. 7(5S), pp.2-72.
Marinina E. S., Nagibin O. A. Scientific substantiation of the main ways of preventing cardiovascular diseases. UNIVERSUM: medicine and pharmacology, 2018. (2 (47)), pp. 4-9.
Okrugin S.A., Garganeeva A.A., Kuzheleva E.A. Evaluation of the influence of myocardial infarction in history and preinfarction state on the duration of the prehospital stage of acute myocardial infarction. complex problems of cardiovascular diseases. 2016.5(1). pp.55-59.
Soleeva S.Sh. Statins and pro-inflammatory cytokines in coronary heart disease after coronary stenting. Journal of Cardiorespiratory Research. 2022. No. 3(2).
Ellamonov S.N., Tashkenbaeva E.N., Abdieva G.A. et al. Factors of progression of arterial hypertension in patients with comorbidity with type 2 diabetes mellitus. Journal of Cardiorespiratory Research, 2021. 2(2).
Word Health Organization. Preventing chronic disease: A vital investment //http:// www.who.int./chp/chronic disease report.
